Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics announced FDA full approval of FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. FILSPARI is the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN. The approval is based on positive long-term results from the PROTECT Study, showing superior kidney function preservation compared to irbesartan over two years.
Key points:
- FILSPARI is an oral, once-daily medication that targets glomerular injury in the kidney
- It demonstrated a statistically significant treatment effect of 1.2 mL/min/1.73 m2/year in eGFR slope
- The drug showed durable benefits on proteinuria and was well-tolerated
- FILSPARI has the potential to become foundational care in IgAN
Travere Therapeutics (Nasdaq: TVTX) will present two posters on classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024. The presentations will focus on the trial designs of:
- The pivotal Phase 3 HARMONY Study
- ENSEMBLE long-term extension study
- Cohort 7 in the Phase 1/2 COMPOSE Study
All studies involve pegtibatinase, a novel investigational enzyme replacement therapy for HCU. Travere believes pegtibatinase could become the first disease-modifying therapy for classical HCU by effectively replacing the deficient CBS enzyme activity. The posters will be presented on September 4, 2024, from 6:15 – 8:15 p.m. GMT+1 at the Rosa Mota Pavilion.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two upcoming investor conferences in August 2024. The company will present at the 2024 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, at 2:30 p.m. ET, and the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, at 12:30 p.m. ET.
A live webcast of the Canaccord Genuity conference presentation will be available on Travere's website investor page, with a replay accessible for up to 30 days after the event. This announcement highlights Travere's commitment to engaging with investors and sharing company updates through these important industry events.
Travere Therapeutics (NASDAQ: TVTX) reported strong Q2 2024 financial results, highlighting the success of FILSPARI® (sparsentan) in treating IgAN. Key points include:
- 521 new patient start forms (PSFs) for FILSPARI, totaling 2,484 since launch
- FILSPARI net product sales of $27.1 million, up 37% from previous quarter
- Total revenue of $54.1 million, including $52.2 million in net product sales
- Cash position of $325.4 million as of June 30, 2024
The company is preparing for the September 5, 2024 PDUFA date for full approval of FILSPARI in IgAN. Travere is also advancing global expansion efforts and progressing its pegtibatinase Phase 3 program for classical homocystinuria.
Travere Therapeutics (NASDAQ: TVTX) has announced that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. Investors can access the webcast and dial-in information on Travere's website at ir.travere.com/events-presentations. An archived version of the call will be available for 30 days on the company's website following the live webcast.
Travere Therapeutics (NASDAQ: TVTX) will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investor page, and a replay will be available for 30 days post-event. The company's management will discuss key developments and insights related to their kidney disease therapeutics pipeline.
Travere Therapeutics (NASDAQ: TVTX) announced on June 11, 2024, that its Compensation Committee granted inducement equity grants to three new employees on June 10, 2024. These grants, consisting of 10,500 inducement restricted stock units (RSUs), are part of the company's efforts to attract new talent. The RSUs are governed by the terms of Travere's 2018 Equity Incentive Plan but were granted outside of this plan as inducements material to the new hires. The RSUs will vest over four years, with 25% vesting each year, contingent upon the employees' continued service with the company.
Travere Therapeutics announced the issuance of inducement equity grants to five new employees under Nasdaq Listing Rule 5635(c)(4) on May 10, 2024.
The grants include stock options for 25,000 shares and restricted stock units (RSUs) for 26,500 shares of common stock. The stock options have an exercise price of $6.30 per share, the closing price on the date of grant, and vest over a four-year period. The RSUs also vest over four years, with 25% of shares vesting annually.
These inducement grants are intended to attract new talent and are issued outside of Travere's 2018 Equity Incentive Plan but adhere to its terms.
Travere Therapeutics, Inc. (Nasdaq: TVTX) will present data on FILSPARI (sparsentan) at the National Kidney Foundation (NKF) Spring Clinical Meetings and the European Renal Association (ERA) Congress. The presentations showcase FILSPARI's efficacy over traditional treatments, highlighting its benefits in patients with IgA nephropathy.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will be participating in upcoming investor conferences including the BofA Securities Health Care Conference on May 15, 2024, and the Jefferies Global Healthcare Conference on June 5, 2024. The live webcasts of the presentations can be accessed on Travere's website with replays available for 30 days after each event.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
